Αρχική World News Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment... World News Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment of Patients with Metastatic NSCLC Από Ogkologos - 14 Απριλίου, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 3475A-D77 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Five Questions With…Fern, Christina, Mary, and Shelley. 26 Μαΐου, 2022 Olaparib approved for 800 prostate and breast cancer patients in England 11 Απριλίου, 2023 Research with integrity – all the fun of the FAIR 8 Αυγούστου, 2023 A new approach to cancer immunotherapy 18 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Coronavirus and cancer – July updates Detecting multiple cancers with a ‘simple’ blood test: Where are we? Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2...